Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2010 Jun 22

PMID 20563900

Citations 4

Authors

Jean-Pierre Devogelaer

Yves Boutsen

Daniel H Manicourt

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is characterized by the occurrence of a host of fractures. According to densitometric values, an operational definition for osteoporosis corresponds to a loss of 25% to 30% (-2.5 T-scores) compared with the mean values of bone mineral density of young premenopausal women. For years, research tried to develop drugs to improve the bone mineral density. According to the compounds, antiresorptive agents are able to decrease the fracture rate by about 30% to 70%, and to increase the bone mineral density. However, the agents increasing the most bone mineral density are not necessarily those that influence the most fracture rates. It has been known for years that parathyroid hormone (PTH) administered cyclically is able to increase bone mineral density. Two analogues of PTH have been developed: PTH (1-34) and PTH (1-84). Both of them are able to increase bone mineral density and reduce the rate of vertebral fracture but not of the hip, nor of nonvertebral fractures, the latter at least for PTH (1-84). Their exact place in the armamentarium of therapy of osteoporosis and their best time of administration are not yet definitely settled. New modes of administration (transdermal, intranasal, oral) will probably become available soon. With all the drugs available today and those still in development, it can be hoped that osteoporosis will become a disease of the past.

Citing Articles

Management of chronic pain in osteoporosis: challenges and solutions.

Paolucci T, Saraceni V, Piccinini G J Pain Res. 2016; 9:177-86.

PMID: 27099529 PMC: 4824363. DOI: 10.2147/JPR.S83574.

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.

Harvey N, Kanis J, Oden A, Nakamura T, Shiraki M, Sugimoto T Osteoporos Int. 2015; 26(9):2347-53.

PMID: 26092062 PMC: 4532707. DOI: 10.1007/s00198-015-3129-7.

Osteoporosis - a current view of pharmacological prevention and treatment.

Das S, Crockett J Drug Des Devel Ther. 2013; 7:435-48.

PMID: 23807838 PMC: 3686324. DOI: 10.2147/DDDT.S31504.

Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat.

Tezval M, Serferaz G, Rack T, Kolios L, Sehmisch S, Schmelz U World J Urol. 2011; 29(4):529-34.

PMID: 21298272 PMC: 3143324. DOI: 10.1007/s00345-011-0652-9.

References

Kaufman J, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky G . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2004; 16(5):510-6. DOI: 10.1007/s00198-004-1713-3. View

Reeve J, Bradbeer J, Arlot M, Davies U, Green J, Hampton L . hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int. 1991; 1(3):162-70. DOI: 10.1007/BF01625448. View

Recker R, Bare S, Smith S, Varela A, Miller M, Morris S . Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone. 2008; 44(1):113-9. DOI: 10.1016/j.bone.2008.09.019. View

Sarkar S, Mitlak B, Wong M, Stock J, Black D, Harper K . Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17(1):1-10. DOI: 10.1359/jbmr.2002.17.1.1. View

Lane N, Sanchez S, Modin G, Genant H, Pierini E, Arnaud C . Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998; 102(8):1627-33. PMC: 509014. DOI: 10.1172/JCI3914. View

Cosman F, Wermers R, Recknor C, Mauck K, Xie L, Glass E . Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009; 94(10):3772-80. DOI: 10.1210/jc.2008-2719. View

Horwitz M, Tedesco M, Garcia-Ocana A, Sereika S, Prebehala L, Bisello A . Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010; 95(3):1279-87. PMC: 2841539. DOI: 10.1210/jc.2009-0233. View

Watts N, Cooper C, Lindsay R, Eastell R, Manhart M, Barton I . Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004; 7(3):255-61. DOI: 10.1385/jcd:7:3:255. View

Cosman F, Lane N, Bolognese M, Zanchetta J, Garcia-Hernandez P, Sees K . Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2009; 95(1):151-8. PMC: 2805490. DOI: 10.1210/jc.2009-0358. View

10.

Finkelstein J, Wyland J, Leder B, Burnett-Bowie S, Lee H, Juppner H . Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009; 94(7):2495-501. PMC: 2708954. DOI: 10.1210/jc.2009-0154. View

11.

Cummings S, Karpf D, Harris F, Genant H, Ensrud K, LaCroix A . Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112(4):281-9. DOI: 10.1016/s0002-9343(01)01124-x. View

12.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

13.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

14.

. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991; 90(1):107-10. DOI: 10.1016/0002-9343(91)90512-v. View

15.

Finkelstein J, Hayes A, Hunzelman J, Wyland J, Lee H, Neer R . The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349(13):1216-26. DOI: 10.1056/NEJMoa035725. View

16.

Cosman F, Nieves J, Zion M, Barbuto N, Lindsay R . Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int. 2007; 19(4):529-35. DOI: 10.1007/s00198-007-0475-0. View

17.

Bruyere O, Roux C, Detilleux J, Slosman D, Spector T, Fardellone P . Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007; 92(8):3076-81. DOI: 10.1210/jc.2006-2758. View

18.

Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V . Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16(5):925-31. DOI: 10.1359/jbmr.2001.16.5.925. View

19.

Kumar S, Matheny C, Hoffman S, Marquis R, Schultz M, Liang X . An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2009; 46(2):534-42. DOI: 10.1016/j.bone.2009.09.028. View

20.

Devogelaer J . Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am. 2007; 32(4):733-57. DOI: 10.1016/j.rdc.2006.09.001. View